Compare HTZ & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | AAPG |
|---|---|---|
| Founded | 1918 | 2009 |
| Country | United States | China |
| Employees | 26000 | 767 |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | HTZ | AAPG |
|---|---|---|
| Price | $2.68 | $16.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.67 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 13.1M | 8.8K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.94 | $290.34 |
| Revenue Next Year | $3.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.51 | $16.92 |
| 52 Week High | $8.44 | $48.45 |
| Indicator | HTZ | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 19.35 | 31.38 |
| Support Level | N/A | N/A |
| Resistance Level | $5.58 | $18.17 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | -0.25 | 0.11 |
| Stochastic Oscillator | 5.84 | 16.05 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.